Narayan Shivapurkar
Overview
Explore the profile of Narayan Shivapurkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciofoaia V, Chen W, Tarek B, Gay M, Shivapurkar N, Smith J
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794273
Chronic pancreatitis (CP) is a rare but debilitating condition with an 8-fold increased risk of developing pancreatic cancer. In addition to the symptoms that come from the loss of endocrine...
2.
Gay M, Drda J, Chen W, Huang Y, Yassin A, Duka T, et al.
Am J Physiol Gastrointest Liver Physiol
. 2024 Jan;
326(3):G291-G309.
PMID: 38252699
Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related deaths worldwide. Chronic inflammation and fibrosis are the greatest risk factors for the development of HCC. Although the cell of origin...
3.
Edwardson M, Shivapurkar N, Li J, Khan M, Smith J, Giannetti M, et al.
J Cereb Blood Flow Metab
. 2023 Sep;
43(12):2130-2143.
PMID: 37694957
Few have characterized miRNA expression during the transition from injury to neural repair and secondary neurodegeneration following stroke in humans. We compared expression of 754 miRNAs from plasma samples collected...
4.
Jolly G, Duka T, Shivapurkar N, Chen W, Bansal S, Cheema A, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345148
CCK receptors are expressed on pancreatic cancer epithelial cells, and blockade with receptor antagonists decreases tumor growth. Activated pancreatic stellate cells or myofibroblasts have also been described to express CCK...
5.
Huber M, Nadella S, Cao H, Kallakury B, Tucker R, Gay M, et al.
Pancreas
. 2023 Apr;
51(9):1118-1127.
PMID: 37078934
Objectives: To analyze whether use of proton pump inhibitors increase the risk for pancreatic cancer in a mouse model and human clinical cohorts. Methods: p48-Cre/LSL-KrasG12D mice that develop precancerous pancreatic...
6.
Shivapurkar N, Gay M, He A, Chen W, Golnazar S, Cao H, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835036
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated deaths worldwide. Treatment with immune checkpoint antibodies has shown promise in advanced HCC, but the response is only 15-20%. We...
7.
Smith J, Chen W, Shivapurkar N, Gerber M, Tucker R, Kallakury B, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36614194
Survival from pancreatic cancer is poor because most cancers are diagnosed in the late stages and there are no therapies to prevent the progression of precancerous pancreatic intraepithelial neoplasms (PanINs)....
8.
Rabiee A, Gay M, Shivapurkar N, Cao H, Nadella S, Smith C, et al.
Clin Pharmacol Ther
. 2022 Sep;
112(6):1271-1279.
PMID: 36087237
High saturated fat diets have been shown to raise blood levels of cholecystokinin (CCK) and induce nonalcoholic steatohepatitis (NASH). CCK receptors are expressed on stellate cells and are responsible for...
9.
Gay M, Cao H, Shivapurkar N, Dakshanamurthy S, Kallakury B, Tucker R, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163821
Nonalcoholic steatohepatitis (NASH) is associated with obesity, metabolic syndrome, and dysbiosis of the gut microbiome. Cholecystokinin (CCK) is released by saturated fats and plays an important role in bile acid...
10.
Malchiodi Z, Cao H, Gay M, Safronenka A, Bansal S, Tucker R, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638432
Pancreatic cancer is resistant to chemotherapy in part due to the dense desmoplastic fibrosis surrounding the tumor, the immunosuppressive cells in the tumor microenvironment (TME), and the early rate of...